AB0069 ASSOCIATION OF NUCLEAR FACTOR OF ACTIVATED T CELLS CYTOPLASMIC 1 (NFATc1) EXPRESSION WITH CARDIOVASCULAR RISK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

Background Nuclear factor of activated T cells (NFAT) is a transcription family that plays crucial role in physiological and immune processes, modulating intracellular extracellular signaling pathways related with several diseases 1,2 . In this regard, it has been involved the pathogenesis rheumatoid arthritis (RA) development cardiovascular (CV) disease 3-5 Given CV one main causes morbidity mortality patients RA 6 , functional studies focused on implication NFAT are potential interest. Objectives To study gene expression two members family, NFATc1 NFATc2 risk developing RA. Methods A total 79 disease-modifying antirheumatic drug-naïve early 7 from Hospital Universitario Marqués de Valdecilla (Santander, Spain) were included study. The relative mRNA peripheral blood was determined by qPCR. Carotid ultrasound data used as surrogate markers subclinical atherosclerosis. association between their clinical characteristics evaluated. Results adjusted sex, age at time traditional factors. statistically significant increase found women compared to men (fold change=+1.18, p=0.035). addition, higher observed dyslipidemia those normal lipid profile p=0.006). With respect this, we also disclosed positive correlation low-density lipoprotein cholesterol levels (r=0.27, p=0.039). No associations detected our patients. findings not expression. Conclusion Our suggests associated abnormalities and, consequently, an increased References [1]Annu Rev Immunol.1997;15:707-747; [2]Nat Immunol.2005;5:472-484; [3]Autoimmun Rev.2006;5:106-110; [4]Immunol Rev. 2010;233:286-300; [5]Front Cardiovasc Med. 2021;8:635172; [6]Arthritis Rheumatol. 2019;71:351-360; [7]Arthritis Rheum.2010;62:2569-2581. Acknowledgements Study supported NVAL 19/18 awarded SR-M (IDIVAL) partially PI18/00043 (ISCIII). Personal funds, SR-M: RD16/0012/0009 (ISCIII-ERDF); VP-C: PREVAL18/01 (IDIVAL); RL-M: Miguel Servet type I CP16/00033 (ISCIII-ESF). Disclosure Interests Fernanda Genre: None declared, Verónica Pulito-Cueto: Alfonso Corrales: Virginia Portilla: Leticia Lera-Gómez: Belén Atienza-Mateo: Oreste Gualillo: Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen MSD, Consultant of: Grant/research support from: MSD Iván Ferraz-Amaro: Santos Castañeda: Raquel López-Mejías: González-Gay Sanofi, Lilly, Celgene, GSK, Janssen, Sara Remuzgo-Martínez: declared